Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia   - Episode 1

Overview of CAR T-cell Therapies in R/R B-cell ALL

, , , ,

Evandro D. Bezerra, MD, provides an overview of current CAR T-cell therapies for relapsed/refractory B-cell acute lymphoblastic leukemia and explores emerging CAR T products under investigation.

Now Viewing
EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL
EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
EP. 3: Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL
EP. 4: Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment
EP. 5: Overview of Available Treatment Options in R/R B-cell ALL
EP. 6: Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
EP. 7: Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
EP. 8: Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
EP. 9: Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy
EP. 10: Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment
EP. 11: Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
EP. 12: Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL
EP. 13: Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy
EP. 14: Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL
EP. 15: Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy
EP. 16: Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy
EP. 17: Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL
EP. 18: Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
EP. 19: Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
EP. 20: Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

  • Can you walk us through the currently available CAR T-cell Therapies for Relapsed / Refractory B-cell ALL, as well as some CAR T products currently being investigated?
    • Please comment on Brexucabtagene autoleucel (TECARTUS®), Tisagenlecleucel (KYMRIAH®), [Obecabtagene autoleucel (Obe-cel) ; Obe-Cel FDA Biologics License Application BLA News Release]